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Abstract 
BACKGROUND: So far, assay-vendor independent quality control (QC) samples for neurochemical 
dementia diagnostics (NDD) biomarkers are not available on the market, which forces NDD laboratories 
to prepare their own QC samples, mostly based on cerebrospinal fluid (CSF) samples rests. 
OBJECTIVE: To prepare and test alternative matrices for QC samples that could facilitate internal and 
external (inter-laboratory) QC of the NDD biomarkers. 
METHODS: Three matrices were tested in this study: (A) human pooled CSF, (B) Aβ peptides spiked 
into human prediluted plasma, and (C) Aβ peptides spiked into solution of bovine serum albumin in PBS. 
All matrices were tested also after supplementation with an antibacterial agent (sodium azide). We tested 
short- and long-term stability of the biomarkers and performed an inter-center variability study. 
RESULTS: NDD biomarkers turned out to be stable in almost all samples stored at different conditions 
for up to 14 days as well as in the samples stored deeply frozen up to one year. Sodium azide did not 
improve the biomarkers stability. Inter-center variability of the samples sent under room temperature 
(pooled CSF, lyophilized CSF, and four artificial matrices) was comparable to the results obtained on 
deeply frozen samples in other large-scale projects. 
CONCLUSION: We believe that it is possible to replace self-made CSF-based QC samples with large-
scale volumes of the QC samples prepared with artificial peptides and matrices, which would greatly 







Neurochemical dementia diagnostics (NDD), along with the amyloid β (Aβ) PET imaging, has become 
the most important modality for the early diagnosis of Alzheimer's disease (AD) [1, 2]. Cerebrospinal 
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fluid (CSF) biomarkers, particularly Aβ peptides, show alterations in very early preclinical stages of the 
disease, probably decades before the onset of the first clinical symptoms [3, 4]. Therefore it is not 
surprising that more and more laboratories are willing to establish NDD as their routine tools either for 
an early AD diagnosis or to increase probability of the underlying AD pathology in clinical trials [5, 6]. 
On the other hand, partially due to the physical-chemical properties of Aβ peptides and Tau proteins, 
quality control (QC) of the NDD analyses is very difficult; large-scale international scientific studies 
performed in the last years [7, 8] have shown that also the inter-laboratory precision of the NDD 
measurements requires further optimization. As a matter of fact, insufficient validation of the NDD 
measurements is considered one of the most important factor preventing CSF biomarkers from general 
acceptance as a routine AD diagnostic tool [9]. 
 So far, an assay-independent QC sample for any of the NDD biomarkers has not been available 
on the market, which forces laboratories to develop their own sample preparation procedures and QC 
materials, most commonly based on pooling of available CSF sample rests. Such approach makes intra-
laboratory QC difficult and inter-laboratory QC even impossible, for at least three reasons: (a) the 
concentrations of the biomarkers in samples prepared by different centers are of course different; (b) 
quality of samples rests used for the preparation of the QC material is not always optimal, and (c) operating 
procedures to prepare the QC material significantly differ among centers. Moreover, longitudinal QC, 
taken together with the growing frequency of the analyses, requires preparation of the QC material in 
very high amounts, which is not always possible in these laboratories that have limited access to large 
number and volumes of the CSF samples. 
 In our previous study [10], we addressed feasibility of the generation of the NDD QC material 
based on large-scale CSF pools. In the current study, we tested also other, partially artificial, matrices and 
sample preparation procedures for the development of potential QC samples.  
 
Materials and Methods 
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1. Preparation of the samples; conditions for the short- and long-term stability testing; influence of the antibacterial 
factor (sodium azide) 
The Ethical Committee of the University of Erlangen-Nuremberg approved use of human CSF samples 
for this study. Short- and long-term stability was evaluated in the following matrices: 
(A) Human pooled CSF without (A0) and with (A+) addition of sodium azide (NaN3, final concentration 
0.1%). Briefly, freshly collected human CSF samples were pooled (to assure anonymity and non-
traceability), frozen and stored at -80°C. For this project, the samples were thawed and pooled again to 
obtain appropriate volumes of homogenous samples; aliquots were then prepared and stored at the 
conditions described below. 
(B) Artificial Aβ peptides (Aβ1-42 and Aβ1-40; AnaSpec Inc., Fremont, USA) spiked into human plasma 
prediluted 1:200 with 0.97% phosphate-buffered saline (PBS, pH 7.4; Amresco, Solon, USA) and Tween 
20 (Roth, Karlsruhe, Germany), without (B0) and with (B+) addition of NaN3 (final concentration 0.1%). 
Briefly, 5 mL of human plasma was diluted with 995 mL of PBS + 500 µL of Tween 20, and divided into 
two equal volumes. To one portion (500 mL), 5 mL of 10% NaN3-stock was added. Recombinant 
powdered Aβ peptides (0.5 mg) were reconstituted in 1 mL of dimethyl sulfoxide (DMSO; Sigma, St. 
Louis, USA) following further dilution 1:1000 (in two steps) in DMSO to the stock-concentration of 500 
ng/mL. These stock solutions were then aliquoted and frozen at -80°C. Immediately before the 
preparation of the aliquots, 250 µL of a peptide/DMSO solution was added to 9.750 mL of prediluted 
plasma (with- and  without NaN3).  
Furthermore, material B was also tested as a mixture of Aβ1-42 and Aβ1-40 in one sample. Briefly, 
artificial peptides were added to the prediluted serum to achieve the same final concentrations as in the 
separate Aβ1-42 and Aβ1-40 samples. 
(C)  Artificial Aβ peptides spiked into 0.04% bovine serum albumin (BSA; Roth, Karlsruhe, Germany) 
prediluted in PBS/Tween 20, without (C0) and with (C+) addition of NaN3  (final concentration 0.1%). 
Briefly, the material C was prepared analogously to the material B with the exception that instead of 
prediluted plasma, 0.04% BSA/PBS+Tween was used as a diluent. 
Lelental et al                                                                                                                                                                                                                                      5 
 
All six types of the samples (three matrices, each with- and without NaN3) were aliquoted immediately 
after the preparation and stored: (a) at room temperature (RT), (b) in a refrigerator (+4°C), and (c) frozen 
at -20°C. One aliquot from each of these six sets was deep frozen (-80°C) immediately after the 
preparation, and served as a reference sample. The remaining aliquots were kept for: 1-7, 10, and 14 days 
following transfer into -80°C. A summary of the samples preparation protocols for the STS testing is 
presented in table 1. After the completion of the storage time (i. e. 14 days), all aliquots of a given sample 
type were thawed and immediately tested in one analytical run (one ELISA or chemiluminescence plate) 
per biomarker. All measurements were performed in duplicates. 
 The influence of NaN3 (antibacterial agent) on the concentrations of the biomarkers was tested 
by the comparison of their concentrations after storage of the samples for five days at room temperature 
with and without NaN3. 
 For long-term stability testing, samples prepared analogously to those for the STS testing were 






STS and LTS tests were performed with the following assays: Aβ1-40 (IBL International GmbH, 
Hamburg, Germany), Aβ1-42 (Innogenetics, Ghent, Belgium and Meso Scale Discovery, Rockville, USA), 
Tau (Innogenetics and Meso Scale Discovery), pTau181 (Innogenetics). 
 
3. Preparation of the freeze-dried samples 
1 mL of CSF aliquots was filled into 2-mL SCHOTT TopLyo® glass vials (SCHOTT AG, Germany), 
and partially stoppered with 13 mm lyophilization stoppers. Freeze-drying of CSF was performed using 
a commercial Martin Christ Epsilon 2-4 LSC freeze-dryer (CHRIST, Germany).  Samples were placed on 
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a heating shelf of the freeze-dryer at a temperature of +4 ⁰C and slowly pre-freezed (1 degree/min) down 
to -80 ⁰C with additional frozen hold step for 3 hrs. Primary and secondary drying was achieved at a 
vacuum of 30 mTorr and 15 mTorr, respectively. The temperature of the samples was monitored during 
the freeze-drying process using sample vials with thermoprobes. Cycle time was 26 hrs. In the end of the 
cycle, freeze-dried samples were closed, removed from the freeze-dryer, sealed to inhibit the 
humidification, and kept in the dark at -80 °C until shipment. Shipment has been done at ambient 
temperatures. Freeze-dried samples were rehydrated with deionized water. 
 
4. Inter-center variability testing (external quality control, EQC) 
For the inter-center variability testing, the participating 25 laboratories obtained the following samples, 
all of them shipped by regular mail at ambient conditions: 
EQC-1: human pooled CSF; 
EQC-2: sample EQC-1 freeze-dried and send to the participating centers as powder to be reconstituted in 
1 mL of distilled water; 
EQC-3: Aβ1-42 + Aβ1-40 dissolved in prediluted plasma. Briefly, 50µL of a 500 ng/mL Aβ1-42 stock and 
320µL of a 500 ng/mL stock Aβ1-40 was diluted in 17 mL of human plasma prediluted 1:200 in 
PBS/Tween. 
EQC-4: Aβ1-42 + Aβ1-40 diluted in plasma, analogously to the material EQC-2, whereas the volumes of 
the spiked stocks were 35µL of Aβ1-42 and 160µL of Aβ1-40. 
EQC-5: Aβ1-42 + Aβ1-40 diluted in BSA/PBS+Tween. Briefly, 50µL of a 500 ng/mL Aβ1-42 stock and 
320µL of a 500 ng/mL Aβ1-40 stock was diluted in 17 mL of 0.04% BSA/PBS+Tween. 
EQC-6: Aβ1-42 + Aβ1-40 diluted in 0.04% BSA in PBS+Tween, analogously to the material EQC-4, 
whereas the volumes of the spiked stocks were 35µL of Aβ1-42 and 160µL of Aβ1-40. 
The summary of the samples for the EQC is presented in table 2. 
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5. Inter-assay imprecision 
For inter-assay imprecision, a set of aliquots of human pooled CSF was prepared and promptly refrozen 
at -80°C. One aliquot was freshly thawed immediately before the analyses, which were performed by 
different operators and on different days in the time span of fourteen months. 
 
Results 
1. Short-term stability 
The results of the short-term stability (STS) testing of the prediluted plasma-based samples (B0 and B+) 
are presented in figures 1 and 2, and the resulting normalized concentrations and their coefficients of 
variation (CV's) are presented in tables 3 and 4. Taken together, both biomarkers turned out stable when 
stored under all three conditions, with only single cases of the concentrations exceeding 80% - 120% 
range of the starting concentrations, irrespectively if the two peptides were tested separately (fig. 1) or as 
a combination (fig. 2). Expectedly, the samples stored at -20°C were even more stable than those stored 
at +4°C or room temperature. 
 The results of the STS testing of the human pooled CSF samples (A0 and A+) are presented in 
the figure 3, and their normalized concentrations and CV's are shown in table 5. Aβ1-40 was very stabile 
in the CSF samples stored at the three tested conditions up to 14 days, whereas Aβ1-42, expectedly, was 
apparently less stable. Interestingly, addition of NaN3 resulted in an improved stability of Aβ1-42 in the 
CSF samples (compare fig. 3c and 3e for Aβ1-42 tested with Innogenetics assays, and 3d and 3e for MSD 
assays). Tau tested with Innogenetics assays (3g and 3h) showed stable concentrations over the whole 
tested period, whereas when tested with MSD assays (3i and 3j), its concentration obviously dropped after 
2 - 3 days of storage. Phosphorylated Tau, expectedly, characterized with stable concentrations up to 14th 
day of storage (fig. 3k and 3l). 
 The results of the STS testing of the peptides diluted in BSA/PBS+Tween (C0 and C+) are 
presented in figure 4, and the corresponding normalized concentrations and CV's are shown in table 6. 
Also in this matrix, Aβ1-40 turned out very stable at all three tested conditions, with apparent drop of 
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concentration in a sample stored for longer than 10 days at room temperature without NaN3 (fig. 4a). 
Interestingly, also Aβ1-42 was relatively stable in this matrix, however, with unexpected and unclear rise 
in its concentration in a RT sample at day 5 when tested with Innogenetics (fig. 4c) but not with MSD 
(fig. 4e) assay. 
 
2. Influence of the antibacterial factor 
The differences in the concentrations of the biomarkers possibly resulting from addition of sodium azide 
are presented in table 7. Application of 0.1% NaN3 apparently did not change starting concentrations of 
the two peptides nor did it influenced their concentrations after 5 days at room temperature.  
 
 
3. Long-term stability 
The results of the long-term stability (LTS) are presented in figure 5. The concentrations of Aβ1-40 in 
the samples stored deeply frozen for one year was apparently stable in all samples, with an exception of 
the sample based on prediluted serum not supplemented with NaN3 (fig. 5a, Mat. B0). Interestingly, Aβ1-
42 was very stable in prediluted serum-based samples (fig. 5b, Mat. B0 and B+) as well as, to a lesser 
degree, CSF samples (fig. 5b, Mat. A0 and A+), but much less stable (in terms of rising and dropping 
concentrations) in a BSA/PBS samples (fig. 5b, Mat. C0 and C+). Tau (fig. 5c) and pTau181 (fig. 5d) 
showed stable concentrations in the CSF samples stored for up to one year. 
 
4. Inter-assay variability 
The results of the inter-assay variability of the biomarkers tested in a pooled human CSF sample are 
presented in fig. 6. Inter-assay imprecision (the number of the repetitions are in brackets) of the 
biomarkers was: 11.7% (25), 10.4% (30), 9.4% (17), and 6.8% (20) for Aβ1-42, Aβ1-40, Tau, and pTau181, 
respectively. 
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5. Inter-center variability 
The results of the biomarkers measurements reported by the participants of the inter-center study are 
presented in figure 7 and table 8. The concentrations in the pooled CSF sample (EQC-1 on figures 7a, c, 
e, and f) showed moderate variability, expectedly slightly higher in case of Aβ1-42 (~25%) than in case of 
other biomarkers, with the lowest variability, as expected, in case of pTau181 (<10%). Comparable 
variability was obtained in case of lyophilized CSF (EQC-2 on figures 7a, c, e, and f), with the exception 
that one participant reported unexpectedly low Aβ1-40 concentration in EQC-2 (particularly when 
compared to his EQC-1 result), which increased overall variability of Aβ1-40 in the lyophilized material 
to 45%. Interestingly to note is that the concentrations of Aβ1-40, Aβ1-42, and pTau181 reported in the 
lyophilized material (EQC-2) paralleled very well, with two or three exceptions, the concentrations in the 
native CSF (EQC-1) but were consistently 20 - 30% lower. In case of Tau, however, a vice versa held true: 
the concentrations in lyophilized material were consistently 50 - 60% higher than in the native CSF. 
 Aβ1-40 in the artificial samples characterized with the variability around 20% (fig. 7b); moreover, 
Aβ1-40 concentrations reported by the participants were almost identical irrespectively of the material 
tested (compare EQC-3 vs. EQC-5 and EQC-4 vs. EQC-6 on fig. 7b), furthermore, the concentrations in 
EQC-4 and EQC-6 were, as expected, almost ideally halves of the concentrations in EQC-3 and EQC-5, 
respectively. 
 Similar holds true for Aβ1-42 (fig. 7d); with overall inter-center variability around 25%, the 
concentrations in EQC-3 and ECQ-5 were very well comparable to each other (excepting the participants 
# 2 and 5), and the same was observed regarding the samples EQC-4 and EQC-6. Furthermore, also in 
case of Aβ1-42, the concentrations in EQC-4 and EQC-6 turned out, as expected, almost ideally 70% of 
the the concentrations in EQC-3 and EQC-5, respectively. 
 
Discussion 
In this study, we present the results of the validation of three matrices (one based on human CSF, and 
two based on artificial solutions) as potential QC samples for NDD biomarkers. 
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 At the beginning of this study (Summer 2011), no commercial material was available for QC of 
the CSF AD biomarkers; meanwhile the situation has improved, as majority of the assay vendors include 
QC samples in their kits; however, it is obvious that such samples are specific-assay-tailored, and cannot 
be reliably used to control the quality of other manufacturers' assays. 
 In our study, three matrices were tested: (A) human pooled CSF, (B) Aβ peptides spiked into 
prediluted human plasma, and (C) Aβ peptides spiked into BSA/PBS solution. Currently most, if not all, 
centers use self-made pooled CSF QC samples for their purposes; this approach requires collection of 
large-scale CSF "rests", which should meet at least minimal quality criteria. Moreover, such CSF rests 
should be collected in a relatively short time, to avoid obsolescing of the CSF samples before required 
volume has been collected. Further limitation of such approach is that it is difficult to control the target 
concentrations of the biomarkers, and, unless a given center has an access to large scale number and 
volumes of pathologic (in sense of neurodegeneration diseases) samples, it is difficult to prepare samples 
with different levels of the biomarkers concentrations. To avoid all these limitations, an artificial sample 
could be prepared by spiking defined amounts of artificial peptides/proteins into a matrix mimicking CSF. 
Human plasma, prediluted 1:200, to achieve the CSF-level of the concentration of albumin, i. e. the most 
abundant CSF protein [11], or the solution of bovine albumin at the concentration of 0.4 g/L, seemed 
the most obvious candidates. Of course such artificial matrices have limitations, too; none of them would 
correspond ideally to the "real" CSF: in prediluted plasma, other blood-derived proteins (for example 
immunoglobulins) are overconcentrated compared to the CSF, whereas they are absent in BSA/PBS 
solution; on the other hand, in both solutions, brain-derived proteins (other than those spiked) are 
completely absent. 
 Following the recommendations by Lisinger et al [12], we tested stability of the biomarkers in 
question in two settings: short-term, which included three temperature conditions, and long-term, which 
was done on the samples kept at -80°C (usual long-term storage condition). 
 To test short-term stability, we applied the isochronous method [13, 14], which means that the 
aliquots were stored at different conditions (room temperature, refrigerator, and -20°C) for a defined time 
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following transfer to the reference condition (deep freezer) for the time remaining to the end of the study, 
and then simultaneously analyzed, together with a reference sample stored at the reference conditions 
from the beginning. For our study, -80°C was chosen as the reference condition, since convincing data 
are available that NDD biomarkers are sufficiently stable at this temperature [15, 16] and deeper freezing 
(on liquid nitrogen, for example) is probably not necessary. The greatest advantage of the isochronous 
method is that all aliquots can be analyzed in the same analytical run (on the same ELISA plate) 
irrespectively of the time they had been stored at a defined condition, which eliminates the influence of 
the inter-assay measurement imprecision. 
 In this study, we also tested if the stability of the biomarkers could be improved by application of 
an antibacterial agent, sodium azide (NaN3), which was brought about by the suggestion of decreased Aβ 
concentrations in CSF samples due to bacterial growth [17]. Our study did not confirm positive influence 
of the antibacterial agent on the stability of the NDD biomarkers, and we do not recommend 
supplementation of QC samples with NaN3. 
 For the long-term stability testing, samples were stored deeply frozen and periodically analyzed 
on ELISA plates of different production charges and, in one case, even with vendor-introduced 
modifications of the assay format. Interpretation of these results must therefore take into consideration 
that the obtained variability is the superposition of the variability of the biomarkers concentrations and 
the inter-assay imprecision of the measurement methods. Long-term variation of measurements, usually 
large compared to the degree of degradation of biomolecules, is one the major problems in the 
determination of long-term stability and shelf-life [18]; on the other hand, we believe that such approach 
is more reliable, compared to the extrapolations of the results of short-term stability with application of 
mathematical equations, as proposed by other investigators [15]. Similarly, Lisinger et al do not 
recommend attempts to estimate long-term stability by extrapolating short-term stability data via the 
Arrhenius-equation [12]. To our opinion, the observed maximal variability in the range of ±20% should 
be considered an acceptable result. As a matter of fact, the concentrations of Aβ1-42 and Aβ1-40 in 
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prediluted plasma without NaN3 supplementation (B0) deviated not more than ±10% in all measurement 
points, i. e. actually within expected inter-assay variability. 
 For the inter-center study, six samples were prepared and sent to the participants under room 
temperature. This approach differs from the protocols of other large-scale inter-center projects, where 
samples were sent frozen [7, 8, 19]. Inter-center variability of the biomarkers obtained in this study in 
pooled CSF was in the range comparable with the results of the studies coordinated by the group of K. 
Blennow, with the variation of Tau and pTau expectedly lower that this of Aβ1-42 [8]. Interestingly, 
comparable variation was obtained with lyophilized sample, with the exception of somehow higher 
variation of Aβ1-40, which can be explained by outlying result reported by one center (#4) and low 
number of the participants. To our best knowledge, no data has been published so far on the inter-center 
variability of Aβ peptides in artificial solutions. The results of this study show not only reasonably low 
variation obtained in these matrices (~20 - 25%) but also plausible distribution of the results across the 
centers: in majority of cases, the participants reported either higher or lower concentrations of a given 
biomarker in all samples, which might denote that the performance of a center, and not the samples, 
require some optimization. Noteworthy is also that the concentrations of the Aβ peptides in the samples 
containing their lower concentrations (70% and 50% of Aβ1-42 and Aβ1-40, respectively) turned out 
indeed correspondingly lower. 
 Our study has at least one limitation: due to dynamical processes of its 
phosphorylation/dephosphorylation, and resulting problems of the molecular instability, it was currently 
impossible to spike Tau and phosphorylated Tau (pTau) into the artificial matrices tested in this study. 
Certainly further work is warranted to facilitate the inclusion of these important biomarkers. 
 In conclusion, we believe that it is possible to replace self-made CSF-based QC samples for the 
NDD with large-scale volumes of the samples prepared with artificial peptides and matrices and at 
different concentrations, which would greatly facilitate intra- and inter-center QC of the NDD 
measurements. 
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Figure legends 
Fig. 1. Results of the short-term stability testing of the samples based on prediluted plasma, when single 
peptides were spiked, presented as normalized concentration (in percent) of the reference samples; 
horizontal axes show storage time (days) at the corresponding storage conditions: RT, room temperature; 
+4°C, refrigerator; -20°C, frozen at -20°C. 
1a. Non-stabilized Aβ1-40; 
1b. Stabilized Aβ1-40; 
1c. Non-stabilized Aβ1-42 (Innotest); 
1d. Stabilized Aβ1-42 (Innotest); 
1e. Non-stabilized Aβ1-42 (MSD); 
1f. Stabilized Aβ1-42 (MSD); 
 
Fig. 2. Results of the short-term stability testing of the samples based on prediluted plasma, when Aβ1-
42 and Aβ1-40 were spiked into one sample. 
2a. Non-stabilized Aβ1-40; 
2b. Stabilized Aβ1-40; 
2c. Non-stabilized Aβ1-42 (Innotest); 
2d. Stabilized Aβ1-42 (Innotest); 
 
Fig. 3. Results of the short-term stability testing of the human pooled CSF samples, presented as 
normalized concentration (in percent) of the reference samples; horizontal axes show storage time (days) 
at the corresponding storage conditions: RT, room temperature; +4°C, refrigerator; -20°C, frozen at -
20°C. 
3a. Non-stabilized Aβ1-40; 
3b. Stabilized Aβ1-40; 
3c. Non-stabilized Aβ1-42 (Innotest); 
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3d. Stabilized Aβ1-42 (Innotest); 
3e. Non-stabilized Aβ1-42 (MSD); 
3f. Stabilized Aβ1-42 (MSD); 
3g. Non-stabilized Tau (Innotest); 
3h. Stabilized Tau (Innotest); 
3i. Non-stabilized Tau (MSD); 
3j. Stabilized Tau (MSD); 
3k. Non-stabilized pTau181 (Innotest); 
3l. Stabilized pTau181 (Innotest); 
 
Fig. 4. Results of the short-term stability testing of the biomarkers diluted in BSA/PBS+Tween, 
presented as normalized concentration (in percent) of the reference samples; horizontal axes show storage 
time (days) at the corresponding storage conditions: RT, room temperature; +4°C, refrigerator; -20°C, 
frozen at -20°C. 
4a. Non-stabilized Aβ1-40; 
4b. Stabilized Aβ1-40; 
4c. Non-stabilized Aβ1-42 (Innotest); 
4d. Stabilized Aβ1-42 (Innotest); 
4e. Non-stabilized Aβ1-42 (MSD); 
4f. Stabilized Aβ1-42 (MSD); 
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Fig. 7. Results of the inter-center variability testing. Horizontal axes represent the participants (in a 
random order); vertical axes present concentrations of the biomarkers (pg/mL).  
7a. Aβ1-40 in liquid CSF (EQC-1) and in lyophilized CSF (EQC-2); 
7b. Aβ1-40 in prediluted plasma (EQC-3 and EQC-4), and in BSA/PBS+Tween (EQC-5 and EQC-6); 
7c. Aβ1-42 in liquid CSF (EQC-1) and in lyophilized CSF (EQC-2); 
7d. Aβ1-42 in prediluted plasma (EQC-3 and EQC-4), and in BSA/PBS+Tween (EQC-5 and EQC-6); 
7e. Tau in liquid CSF (EQC-1) and in lyophilized CSF (EQC-2); 
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